Should intravenous iron be upfront therapy for iron deficiency anemia?

Pediatric Blood and Cancer

Volumn 56, Issue 4, 2011, Pages 511-512

  Auerbach, Michael ^a  

^a Auerbach Hematology and Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; FERRIC CARBOXYMALTOSE; FERRIC HYDROXIDE SUCROSE; FERUMOXYTOL; IRON DEXTRAN; IRON ISOMALTOSIDE; MONOFER; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

DRUG EFFICACY; DRUG SAFETY; HUMAN; IRON DEFICIENCY ANEMIA; IRON THERAPY; NOTE; PRIORITY JOURNAL;

ANEMIA, IRON-DEFICIENCY; CHILD; FERRIC COMPOUNDS; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; IRON-DEXTRAN COMPLEX; MOLECULAR WEIGHT;

EID: 79551637984     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22981     Document Type: Note

References (10)

1. Marchasin S, Wallerstein RO. The treatment of iron-deficiency anemia with intravenous iron dextran. Blood 1964; 23: 354-358.
2. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA 1980; 243: 1726-1731.
3. Chertow GM, Mason PD, Vaage-Nilsen O, et al. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004; 19: 1571-1575.
4. Chertow GM, Mason PD, Vaage-Nilsen O, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378-382.
5. Mamula P, Piccoli DA, Peck SN, et al. Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002; 34: 286-290.
6. Chandler G, Harchowal J, MacDougall IC. Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis 2001; 38: 988-991.
7. Ondo WG. Intravenous iron dextran for refractory restless legs syndrome. Sleep Med 2010; 11: 494-496.
8. Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al. Time-dependent association between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070-3080.
9. Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15: 1623-1632.
10. Hoen B, Paul-Dauphin A, Kessler M. Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol 2002; 57: 457-461.